EPHB2 and rheumatic disorder: Only EphB2 and THEX1 remained significantly recognized by respectively 34% and 60% of sera samples from patients with SSc compared to 14% and 28% (P = 2.10−4, P = 3.10−8) of sera samples from all controls including sera samples from healthy controls and from patients with other rheumatic diseases (Fig 1).